MENLO PARK, Calif., November 6, 2014 - Geron Corporation (Nasdaq: GERN) today announced that five abstracts describing clinical and non-clinical data on imetelstat have been accepted for presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Francisco, California from December 6-9, 2014. The abstracts were published today on the ASH website at www.hematology.org.
Oral Presentations
Two abstracts containing clinical data on imetelstat were selected for oral presentation. One abstract contains an analysis of safety and efficacy data from the clinical trial in myelofibrosis (MF) patients. The abstract updates the preliminary data from this trial that was presented at ASH in December 2013. The second abstract contains an analysis of the effect of imetelstat treatment on CALR mutations detected in essential thrombocythemia patients. The abstract supplements a prior analysis of JAK2V617F mutations presented at the European Hematology Association Congress in June 2013.
Title: Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study (Abstract #634)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Prognosis, Outcome, and Novel Therapies
Session Date: Monday, December 8, 2014
Session Time: 4:30 p.m. - 6:00 p.m. PT
Presentation Time: 5:15 p.m. PT
Title: Monitoring of CALR Allele Burden in Patients with Essential Thrombocythemia Treated with Imetelstat, a Telomerase Inhibitor, Reveals Rapid and Substantial Molecular Responses (Abstract #408)
Session Name: 634. Myeloproliferative Syndromes: Clinical: Mutation Profiling in Prognosis and Therapy
Session Date: Monday, December 8, 2014
Session Time: 10:30 a.m. - 12:00 p.m. PT
Presentation Time:11:45 a.m. PT
Poster Presentations
Three abstracts containing non-clinical data on imetelstat were selected for presentation as posters. In these studies, the investigators evaluated the potential mechanisms of action of imetelstat in various non-clinical models of myeloid malignancies, such as MF and acute myeloid leukemia, to support broader clinical development of the drug.
Title: Effects of Imetelstat on CD34+ Cells of Patients with Myelofibrosis (Abstract #1879)
Session Name: 635. Myeloproliferative Syndromes: Basic Science: Poster I
Session Date: Saturday, December 6, 2014
Session Time: 5:30 p.m. - 7:30 p.m. PT
Title: Inhibition of Telomerase with Imetelstat is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML) (Abstract #2322)
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Session Date: Sunday, December 7, 2014
Session Time: 6:00 p.m. - 8:00 p.m. PT
Title: Imetelstat (GRN163L), a Telomerase Inhibitor Selectively Affects Malignant Megakaryopoiesis in Myeloproliferative Neoplasms (MPN) (Abstract #4582)
Session Name: 635. Myeloproliferative Syndromes: Basic Science: Poster III
Session Date: Monday, December 8, 2014
Session Time: 6:00 p.m. - 8:00 p.m. PT
In accordance with ASH policies, abstracts submitted to the ASH annual meeting are embargoed from the time of submission. To be eligible for presentation at the ASH annual meeting, information contained in the abstract, as well as additional data and information to be presented at the annual meeting, may not be made public before the abstract has been presented in connection with the ASH annual meeting.
Webcast Investor Event
Management will be hosting a live webcast of an analyst and investor meeting at 7:00 p.m. PT on December 8, 2014 to discuss the imetelstat data presented at the ASH Annual Meeting and Exposition. The audio and slide presentation will be accessible at www.geron.com on the Investor Relations pages, under Events. Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
Help employers find you! Check out all the jobs and post your resume.
